Xiangjie Di

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 12

Top Topics

Induced Pluripotent Stem Cells

Top Venues

Journal of clinical medicine

Clinical drug investigation

This page only lists publications with an associated author ORCID identifier.

Publications

Qi Shen, Mengyu Zhang, Ying Jin, Xiangjie Di, Runhan Liu, Zhenlei Wang
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Novel Recombination Human Nerve Growth Factor in Healthy Chinese Subjects. CNS drugs 37 (3) (2023)
Qi Shen, Mengyu Zhang, Ying Jin, Xiangjie Di, Runhan Liu, Zhenlei Wang
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Novel Recombination Human Nerve Growth Factor in Healthy Chinese Subjects. CNS drugs (2023)
Qi Shen, Mengyu Zhang, Ying Jin, Xiangjie Di, Runhan Liu, Zhenlei Wang
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Novel Recombination Human Nerve Growth Factor in Healthy Chinese Subjects. CNS drugs 37 (3) (2023)
Qi Shen, Mengyu Zhang, Ying Jin, Xiangjie Di, Runhan Liu, Zhenlei Wang
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Novel Recombination Human Nerve Growth Factor in Healthy Chinese Subjects. CNS drugs 37 (3) (2023)
Qi Shen, Ying Jin, Xiangjie Di, Chao Hu, Runhan Liu, Ying Wang, Xiaohui Qi, Yongsheng Wang, Zhenlei Wang
Correction: Pharmacokinetics and Safety of Erenumab after a Single Subcutaneous Injection Dose in Healthy Chinese Subjects. Clinical drug investigation (2023)
Xiangjie Di, Xiao Liang, Chao Shen, Yuwen Pei, Bin Wu, Zhiyao He
Carbohydrates Used in Polymeric Systems for Drug Delivery: From Structures to Applications. Pharmaceutics 14 (4) (2022)
Yanghui Zhu, Xiaoyu Wang, Zhaoyang Chen, Lingyan Zhou, Xiangjie Di, Ping Fan, Zhiyao He
Anlotinib Suppressed Ovarian Cancer Progression via Inducing G2/M Phase Arrest and Apoptosis. Journal of clinical medicine 12 (1) (2022)
Qi Shen, Ying Jin, Xiangjie Di, Chao Hu, Runhan Liu, Ying Wang, Xiaohui Qi, Yongsheng Wang, Zhenlei Wang
Pharmacokinetics and Safety of Erenumab after a Single Subcutaneous Injection Dose in Healthy Chinese Subjects. Clinical drug investigation 42 (7) (2022)
Yanghui Zhu, Xiaoyu Wang, Zhaoyang Chen, Lingyan Zhou, Xiangjie Di, Ping Fan, Zhiyao He
Anlotinib Suppressed Ovarian Cancer Progression via Inducing G2/M Phase Arrest and Apoptosis. Journal of clinical medicine 12 (1) (2022)
Yanghui Zhu, Xiaoyu Wang, Zhaoyang Chen, Lingyan Zhou, Xiangjie Di, Ping Fan, Zhiyao He
Anlotinib Suppressed Ovarian Cancer Progression via Inducing G2/M Phase Arrest and Apoptosis. Journal of clinical medicine 12 (1) (2022)
Ying Jin, Xiangjie Di, Lisha Fu, Mengyu Zhang, Neng Qiu, Runhan Liu, Fangqun Li, Xiaohui Qi, Xiaoxu Wang, Yongsheng Wang, Zhenlei Wang
An ultra-performance LC-MS/MS method for determination of JRF103 in human plasma: application in first in-patient study. Bioanalysis 14 (17) (2022)
Zhenlei Wang, Xinghai Li, Ying Jin, Runhan Liu, Xiangjie Di, Yi Zhou, Ying Wang, Lei Fan, Yuanwei Chen, Yongsheng Wang, Li Zheng
Safety, Efficacy, and Pharmacokinetics of HP501 in Healthy Volunteers and Hyperuricemic Patients: A Phase I/IIa Study. The Journal of clinical endocrinology and metabolism 107 (6) (2022)